Novartis: canakinumab shows positive results.

(CercleFinance.com) - Novartis has said that a subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with monoclonal antibody canakinumab in a new analysis of a phase III trial.


The results - presented at the American Heart Association scientific sessions - also showed a 31% reduction in cardiovascular death and a 31% reduction in all-cause mortality in patients whose inflammation - as measured by hsCRP - decreased below 2mg/L three months after starting canakinumab.

Separately, Sandoz, a Novartis division, unveiled data at the American College of Rheumatology (ACR) annual meeting in San Diego, reinforcing the clinical basis for switching to Sandoz biosimilar medicines.

Novartis has also said that it is planning to present new data across broad range of breast cancer patient populations, combination treatments and lines of therapy at the annual San Antonio Breast Cancer Symposium, next month in San Antonio.

Copyright (c) 2017 CercleFinance.com. All rights reserved.